IL-6 might induce tumor immunosuppression by decreasing effector T-cells by enhancing cancer glucose uptake and by increasing regulatory cells through HIF1α and VEGF function via hypoxia-pseudohypoxia-mediated HIF1α activation. Here, HIF1A is linked to neoplasm.